Clover Health beats on revenue; issues guidance

May 17, 2021 7:43 AM ETClover Health Investments, Corp. (CLOV)CLOVBy: Meghavi Singh, SA News Editor
  • Clover Health (NASDAQ:CLOV): Q1 net loss of $48.42M
  • Revenue of $200.3M (+21.0% Y/Y) beats by $7.71M.
  • FY2021 guidance: Medicare Advantage membership is expected to be in the range of 68,000 - 70,000 by December 31, 2021, a growth rate of 17% - 21% as compared to year end 2020.
  • Total revenues are expected to be in the range of $810 - $830 million vs. consensus of $822.49M, inclusive of a preliminary estimate of approximately $20 - $30 million of revenue generated from Direct Contracting.
  • CMS benchmark expenditures under management for Direct Contracting are expected to be in the range of $700 - $800 million.
  • Total Medicare spend under management, which includes revenues from the Medicare Advantage program plus the estimated CMS benchmark expenditures for Direct Contracting, is expected to be in the range of $1.5 - $1.6 billion.
  • Normalized MCR (Non-GAAP) for Medicare Advantage is expected to be in the range of 94% - 97%.
  • MCR for Direct Contracting is expected to be approximately 100%, net of savings targets required by the Centers for Medicare & Medicaid Services (“CMS”).
  • Adjusted Operating Expenses (Non-GAAP) is expected to be between $250 and $270 million, reflecting the use of a portion of the proceeds from the Merger to make investments in marketing, network expansion and technology to support future growth.
  • Normalized Adjusted EBITDA loss (Non-GAAP) is expected to be in the range of $(240) - $(190) million.
  • Shares +3.75% PM.
  • Press Release

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.